Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 10:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled Insulin Clear all
Completed Phase 2 Interventional

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

NCT00143104
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
3
States / cities
Glendale, Arizona • Fresno, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2008 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

Compare Two Dosing Algorithms in Insulin-Naive Patients With Type 2 Diabetes Mellitus

NCT00391209
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder, intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
379 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Santa Ana, California • Washington D.C., District of Columbia • Hollywood, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 24, 2026, 10:57 AM EDT
Withdrawn Not applicable Interventional

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

NCT01459133
View directory record Official record
Conditions
Diabetes
Interventions
Technosphere® Insulin Inhalation System
Drug
Lead sponsor
South Orange County Endocrinology
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2015 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 2 Interventional Results available

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

NCT00662857
View directory record Official record
Conditions
Diabetes Mellitus: Type 1
Interventions
Technosphere Insulin® Inhalation Powder, RAA Population
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Chula Vista, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Not applicable Interventional

Inspiratory Muscle Strength Training in Adults With Type 2 Diabetes

NCT05643768
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension
Interventions
Inspiratory muscle strength training (IMST)
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

US Inhaled Insulin Therapeutic Choice Questionnaire Study

NCT00139763
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Educational Materials
Procedure
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
42
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus

NCT01786707
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Autologous stem cells, Hyperbaric oxygen therapy, Insulin, Metformin
Biological · Other · Drug
Lead sponsor
Rodolfo Alejandro
Other
Eligibility
45 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 24, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional Results available

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

NCT01196104
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Technosphere® Insulin Inhalation Powder, Insulin Aspart, Insulin Glargine
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
29
States / cities
Mobile, Alabama • Fresno, California • Long Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

NCT00757367
View directory record Official record
Conditions
Healthy Subjects
Interventions
TI Inhalation Powder
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

NCT01445951
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere® Insulin with MedTone C Inhaler, Technosphere ®Insulin with Gen2 Inhaler, Insulin Aspart in combination with a basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
58
States / cities
Burlingame, California • Escondido, California • Huntington Beach, California + 50 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp

NCT01874392
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Investigational inhaled insulin (Technosphere), Artificial Pancreas (AP) device (APS©)
Drug · Device
Lead sponsor
Sansum Diabetes Research Institute
Other
Eligibility
21 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

A Clinical Trial Assessing the Impact of the Availability of Inhaled Insulin on Glucose Control

NCT00134147
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2008 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

NCT00356109
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Human Insulin Inhalation Powder, Injectable insulin, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
14
States / cities
Aurora, Colorado • Miami, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 24, 2026, 10:57 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD

NCT03307512
View directory record Official record
Conditions
Safety and Tolerability
Interventions
inhaled human insulin, Insulin Lispro (Humalog U-100)
Drug
Lead sponsor
Dance Biopharm Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

NCT00370565
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2007 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes

NCT00315952
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Exubera
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Sep 24, 2026, 10:57 AM EDT
Terminated Phase 3 Interventional

Effect of Inhaled Pre-prandial Human Insulin on Blood Glucose Control in Type 2 Diabetes

NCT00427154
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
rosiglitazone, inhaled human insulin, metformin, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
103
States / cities
Hueytown, Alabama • Ozark, Alabama • Tuscaloosa, Alabama + 95 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes

NCT00437112
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Greenbrae, California • Topeka, Kansas • Toms River, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 24, 2026, 10:57 AM EDT
Recruiting Phase 2 Interventional

INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes

NCT07224321
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Technosphere Insulin, Basal insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
6 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional Results available

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

NCT03324776
View directory record Official record
Conditions
Type2 Diabetes
Interventions
Afrezza Inhalant Product
Drug
Lead sponsor
Model Clinical Research LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 24, 2026, 10:57 AM EDT
Recruiting Phase 2Phase 3 Interventional

Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes

NCT06535789
View directory record Official record
Conditions
Diabetes, Gestational, Pregnancy Complications, Glucose Metabolism Disorders, Glucose Intolerance During Pregnancy
Interventions
Inhaled Technosphere Insulin
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Santa Barbara, California • Aurora, Colorado • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 3 Interventional

Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes

NCT00355849
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Fresno, California • Pomona, California • West Palm Beach, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 4 Interventional

A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

NCT00367445
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2008 · Synced Sep 24, 2026, 10:57 AM EDT
Completed Phase 4 Interventional Results available

Afrezza® Dosing Optimization Study

NCT04849845
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Afrezza Dose 1, Afrezza Dose 2
Combination Product
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
2
States / cities
Escondido, California • Walnut Creek, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Sep 24, 2026, 10:57 AM EDT